

Development of novel AAV-based **** gene therapy for hearing loss

Yonsei University



OTHERS	Hit
Product Type	Gene & Nucleic acids
Indication	Genetic hearing loss, Age-related hearing loss, Noise-induced hearing loss
Target	****
MoA(Mechanism of Action)	Precise and targeted supplementation of **** in cochlear outer hair cells using AAV to overcome the dominant-negative effects of **** mutations and restore reduced **** expression associated with age-related and noise-induced hearing loss
Competitiveness	Our research team possesses multidisciplinary expertise spanning molecular cell biology, genomic analysis, <i>in vivo</i> animal modeling, and electrophysiology, providing a strong foundation for the development of AAV-**** gene therapy for sensorineural hearing loss. Building on this integrated research platform, the team is well positioned to identify unmet clinical needs, elucidate disease mechanisms, and translate mechanistic insights into innovative therapeutic strategies.
Development Stage	Hit
Route of Administration	Inner ear local delivery (Round window membrane injection)

Any unauthorized distribution or reproduction of this material is strictly prohibited.